INTRODUCTION {#sec1-1}
============

The science of lipidology from the earliest work of Nikolai Antischkow have expanded its tentacles to various lipid and lipoprotein biomarkers for depicting risk for atherosclerotic cardiovascular diseases (ASCVD).[@ref1] Alongside the science also evolved to stratify and quantify the nature and potency of various lipid biomarkers including total cholesterol, triglycerides, LDL-cholesterol(LDLc) and HDL-cholesterol(HDLc).[@ref2] Two important lipid related risk assessment emerged for the assessment of ASCVD, which include the villainous one (LDL-cholesterol) and the good HDL-cholesterol.[@ref3]

Earlier biotechnology did not provide clinically feasible solutions for lipoprotein measurements. Friedewald et al emerged on the clinical horizon as a panacea by simplifying LDLc measurements through a calculated method which involved total cholesterol, triglycerides and HDLc.[@ref4] Though criticism and limitations in terms of requirement of fasting sample, unsuitability for chylous specimens and Frederickson classified type-I hypercholesterolemia were the major limitations for this calculated LDLc,[@ref5] still the calculated LDLc (cLDLc) got slowly incorporated into the labs and received recommendations from various authorities.[@ref6],[@ref7] Alongside the directly measuring clinically suitable technologies for measuring LDLc also evolved, became simplified by removing multiple steps and to some extent cost-effective and less labor intensive. Current trend within labs depicts more shift towards directly measurement techniques of mLDLc (measured LDLc). Though mLDLc technologies seems more promising for highlighting underlying ASCVD, still erroneous results in presence of high triglycerides and related technical limitations downgrade the clinical yield of these slightly expensive methodologies.[@ref8]-[@ref10] Moreover, many regional and new equations have emerged which support a more valuable use of indirect LDLc calculation methods.[@ref11]-[@ref14] Therefore, in comparative terms adopting an accurate calculation based method for cLDLc can be less labor-intensive and cost-effective but will laboratory reporting more precise.

With this background information the study the correlation and concordance between calculated LDL (cLDLc), measured LDL (mLDLc). The objective was to study the difference of these measured and calculated LDL methods within groups formulated based upon glycemic status, Insulin Resistance status, nephropathy status and metabolic syndrome.

METHODS {#sec1-2}
=======

This cross-sectional study was conducted at PNS HAFEEZ hospital (Islamabad) in liaison with department of chemical pathology and clinical endocrinology, Armed Forces Institute of Pathology (AFIP) from January-2016 to July-2017. Our target population were adult subjects who were referred to the department of pathology in fasting for the evaluation of fasting plasma lipid profile. Subject selection was based upon "non-probability convenience sampling". Subjects with chronic/acute disorder, pregnancy, indoor cases, using any medication were not included in the study. Subjects were formally consented after explanation of study related requirements and use of data for publication purpose. All finally selected participants signed a written consent form as per the hospital's ethical review committee. After enrollment, subjects were interviewed as per a questionnaire and general clinical evaluation was carried out. Anthropometric indices including height, weight, waist and hip circumference were measured as per WHO protocol.[@ref15]

Blood (10 ml approx.) was drawn from finally selected subjects (n=232) in plain bottles, EDTA and in Na-Fluoride tubes for measuring various biochemical parameters. Fasting plasma glucose (FPG) was measured by GOD-PAP method, glycated hemoglobin by fast ion-exchange resin separation method and serum insulin by chemiluminescence's technique on Immulite® 1000. CHOD-PAP and GPO-PAP methods were used to measure cholesterol and triglycerides. mLDLc and HDLc were measured by cholesterol esterase method on ADVIA 1800 clinical chemistry system. Samples were urine albumin creatinine ratio (UACR) were collected for 174 subjects and analysis was carried out on imunoturbidimetric method on ADVIA 1800. Homeostasis Model Assessment for insulin resistance (HOMA-IR) was calculated as per the method of Mathew's et al.[@ref16] LDL-cholesterol was measured using Friedewald's formula.[@ref4] During specimen processing few samples were lost due to technical reasons including hemolysis, insufficient quantity and lack of patient follow up for repeat testing.

Grouping was done as:

1-Triglycerides related groups were as: Group-1(Fasting triglycerides: \<1.0 mmol/L), Group-2 (Fasting triglycerides: 1.0-1.99 mmol/L) and Group-3 (Fasting triglycerides: \>1.99 mmol/L)2-UACR groups classified as: Group-1: \< 2.5 mg/g and Group-2: \>2.4 mg/g.

Data Analysis {#sec2-1}
-------------

All data was entered into Excel software and later transferred to SPSS-15. Descriptive statistics for all parameters were calculated in terms of mean and standard deviation. Graphs were generated by employing both Excel and SPSS software.

Pearson's correlation was utilized to correlation between mLDLc and cLDLc and also between other biochemical biomarkers. Kendall's Coefficient of concordance method was utilized to see the concordance between mLDLc and cLDLc. One way ANOVA along with Tukey's post-hoc analysis was used to compare mLDLc and cLDLc between various groups formulated based upon fasting triglycerides levels. Paired-t statistics was used to compare the mLDLc and cLDLc between nephropathy groups as assessed by UACR.

RESULTS {#sec1-3}
=======

Descriptive statistics are shown in [Table-I](#T1){ref-type="table"}. There were 122 females and 110 males. There was significant positive linear correlation between mLDLc and cLDLc as depicted in [Fig.1](#F1){ref-type="fig"}. The correlation between biochemical parameters demonstrated and measured and calculated methods of LDL is shown in [Table-II](#T2){ref-type="table"}. The concordance between mLDLc and cLDLc as measured by Kendall's Coefficient of concordance is shown in [Table-III](#T3){ref-type="table"}. One way ANOVA followed by Tukey's post-hoc analysis between various groups formulated based upon fasting triglycerides levels only demonstrated significance differences (p=0.004) between group-1 and group-2 for mainly mLDLc \[{Group-1:Mean=2.40, (2.19-2.61), n=43}, {Group-2:Mean=2.81, (2.69-2.92), n=136}, \[{Group-3:Mean=2.59, (2.37-2.81), n=53}\] in comparison to cLDLc \[{Group-1:Mean=2.63, (2.43-2.84), n=43}, {Group-2:Mean=2.85, (2.76-2.93), n=136}, \[{Group-3:Mean=2.75, (2.60-2.90), n=53}\]. ([Fig.2](#F2){ref-type="fig"}) [Fig.3](#F3){ref-type="fig"} demonstrates calculated method for LDLc to be higher among subjects with nephropathy in comparison to mLDLc.

###### 

Descriptive statistics for data.

  Parameters                                                      n     Mean    Std. Deviation   
  --------------------------------------------------------------- ----- ------- ---------------- -------
  Age (years)                                                     232   46.56   0.785            11.95
  Body Mass Index(BMI)                                            232   27.13   0.35             5.22
  Waist to hip ratio (WHpR)                                       232   0.93    0.043            0.08
  Fasting plasma Glucose (mmol/L)                                 232   5.62    0.148            2.26
  Total cholesterol (mmol/L)                                      232   4.48    0.039            0.61
  Triglycerides (mmol/L)                                          232   1.61    0.049            0.75
  HDLc (mmol/L)                                                   230   0.98    0.017            0.26
  mLDLc (mmol/L)                                                  230   2.68    0.048            0.72
  cLDLc (mmol/L)                                                  232   2.79    0.036            0.55
  HbA1c (%                                                        228   5.76    0.064            0.97
  Homeostasis Model Assessment for Insulin Resistance (HOMA-IR)   228   2.83    0.256            3.86
  UACR (mg/g)                                                     174   2.74    0.370            4.90

###### 

Pearson correlation between various biochemical risk biomarkers and mLDLc and cLDLc.

  Parameter         Statistics            cLDLc (mmol/L)   mLDLc (mmol/L)
  ----------------- --------------------- ---------------- ----------------
  HOMA-IR           Pearson Correlation   -0.032           -0.035
  Sig. (2-tailed)   0.627                 0.598            
  n                 228                   227              
  UACR (g/mg)       Pearson Correlation   0.083            0.098
  Sig. (2-tailed)   0.276                 0.197            
  n                 174                   173              
  HbA1c (%)         Pearson Correlation   -0.132^\*^       -0.011
  Sig. (2-tailed)   0.046                 0.864            
  n                 228                   226              
  Insulin (mIU/L)   Pearson Correlation   0.026            0.001
  Sig. (2-tailed)   0.696                 0.989            
  n                 228                   227              

###### 

Concordance between mLDLc and cLDLc.

  Parameter        n     Mean   Std. Deviation   Kendall's Coefficient of concordance   Asymp. Sig. (p-Value)
  ---------------- ----- ------ ---------------- -------------------------------------- -----------------------
  mLDLc (mmol/L)   230   2.68   0.723            0.055                                  \<0.001
  cLDLc (mmol/L)   230   2.78   0.538                                                   

![Correlation between measured LDL cholesterol (mLDLc) and calculated LDL cholesterol (cLDLc) \[Pearson correlation coefficient (r) = 0.468, \<0.001\].](PJMS-35-388-g001){#F1}

![Histogram demonstrating differences in mean mLDLc and cLDLc among fasting triglycerides groups.](PJMS-35-388-g002){#F2}

![Histogram demonstrating differences in mean mLDLc and cLDLc among patients with UACR and low UACR (n=174).](PJMS-35-388-g003){#F3}

DISCUSSION {#sec1-4}
==========

Our study has shown significant positive correlation and concordance between mLDLc and cLDLc. However, the results between the two LDLc measures remain significantly different with regards to association with evaluated biochemical parameters implying that two parameters act to measure different aspects of disease. There is much evidence supporting the observed differences between mLDLc and cLDLc in literature. An earlier Pakistani study by Fawwad A et al showed triglyceride related bias, with recommendations for using direct methods.[@ref17] Jun KR et al in a recent study has demonstrated that Fiedewld's equation may underestimate coronary heart disease in comparison to direct methods.[@ref18] Another study from Iran showed strong correlation between the calculated and measured LDLc but highlighted that Friedewald's equation overestimate LDLc.[@ref19] In contrasts to above finding literature Kamezaki F et al have concluded that direct measuring LCLc methods over estimates, rather than underestimates LDLc results.[@ref20] Chotkowska et al have also highlighted mLDLc methods once compared with gold standard technique of ultracentrifugation to demonstrate a positive bias in comparison to Friedewald's equation.[@ref21]

Taken together the contrasts in literature with regards to methodologies over and underestimating triglycerides, possible explanation could be: First of all, as the triglyceridemia affects LDLc measures in calculated methods which is evident by the use of different factors to manage VLDL in serum triglyceride calculation, so calculated methods are inherently biased to the presence of triglyceride adjustment.[@ref22],[@ref23] Secondly, variation between LDL associations with other biochemical risks and between mLDLc and cLDLc may be attributed to differences measuring technologies as Kamezaki F et al and Chotkowska et al have utilized ultra-centrifugation methods in contrasts our methodology.[@ref17]-[@ref21] Finally, regional differences have been highlighted by multiple studies, and thus it becomes pertinent to interpret our LDLc calculations with the perspective of interpreting racial and regional factors. However, we feel as authors that the differences based upon race and regions are marginal and will not final affect final interpretation of the data.[@ref24],[@ref25]

Limitations of the study {#sec2-2}
------------------------

This was a cross-sectional study which was meant to highlight only association between mLDLc and cLDLc, where we understand that various other homogenous methods are now available to measure LDLc directly. So results are bound to be different between different methodologies. Secondly, the sample size is small which can lead to possible type-2 statistical error. A randomized controlled study with more sample size incorporating various available homogenous mLDLc should be carried out to augment or refute our findings.

The study is considered clinically important as decades old Friedewald's equation for LDLc calculation looked destined to end up as an obsolete lipid biomarker, but the current study provides some life to cLDLc on account of moderate correlation, concordance, and slight degree of association in terms of nephropathy and with diabetogenic tendencies. Being cost-effective, least labor intensive and with aforementioned statistical information from our study we feel it will still remain useful in developing economies for some time to come.

CONCLUSION {#sec1-5}
==========

Though cLDLc have shown concordance with mLDLc along with moderate correlation and has been proven to depict some degree of lipid related risk for nephropathy and diabetic indices, still cLDLc over estimates LDLc in comparison to mLDLc. However, till the homogenous methods are not fully evolved in biotechnology and become cost-effective, cLDLc can be useful in lipid associated risk prediction.
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